Cambridge, MA, January 5, 2022, (Dow Jones Newswires) — Blueprint Medicines Corp. on Wednesday said it designated Kate Haviland to succeed Jeff Albers as president and chief executive, effective April 4.
The Cambridge, Mass., precision-therapy company said Mr. Albers, who also serves as chairman, will become executive chairman on that date.
Ms. Haviland, who joined Blueprint in January 2016 and has been chief operating officer since January 2019, will also join the board, the company said.
Blueprint said Christina Rossi, currently chief commercial officer, will succeed Ms. Haviland as chief operating officer.
The company said Mr. Albers, who joined as CEO in 2014, will serve as executive chairman through the end of the year and then continue as chairman.